1
Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
2
Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
3
International Textbook of Diabetes Mellitus. 4th ed. John Wiley & Sons, Incorporated 2015. http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=1895437
4
Type 1 diabetes in adults: diagnosis and management | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/ng17
5
Type 2 diabetes in adults: management | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/ng28
6
Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. The Lancet Published Online First: February 2017. doi:10.1016/S0140-6736(17)30058-2
7
Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. The Lancet 2014;383:69–82. doi:10.1016/S0140-6736(13)60591-7
8
Matheus AS de M, Tannus LRM, Cobas RA, et al. Impact of Diabetes on Cardiovascular Disease: An Update. International Journal of Hypertension 2013;2013:1–15. doi:10.1155/2013/653789
9
Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858717300335
10
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673614607947
11
Holman RR, Paul SK, Bethel MA, et al. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine 2008;359:1577–89. doi:10.1056/NEJMoa0806470
12
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998;352:854–65. doi:10.1016/S0140-6736(98)07037-8
13
Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine 2008;358:2545–59. doi:10.1056/NEJMoa0802743
14
Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288–98. doi:10.1007/s00125-009-1470-0
15
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. New England Journal of Medicine 2011;364:818–28. doi:10.1056/NEJMoa1006524
16
Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010;340:b5444–b5444. doi:10.1136/bmj.b5444
17
Duckworth W, Abraira C, Moritz T, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. New England Journal of Medicine 2009;360:129–39. doi:10.1056/NEJMoa0808431
18
Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 2015;372:2197–206. doi:10.1056/NEJMoa1414266
19
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine 2008;358:2560–72. doi:10.1056/NEJMoa0802987
20
Wong MG, Perkovic V, Chalmers J, et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care 2016;39:694–700. doi:10.2337/dc15-2322
21
Giorgino F, Home PD, Tuomilehto J. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear? Diabetes Care 2016;39:S187–95. doi:10.2337/dcS15-3023
22
Gæde P, Lund-Andersen H, Parving H-H, et al. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. New England Journal of Medicine 2008;358:580–91. doi:10.1056/NEJMoa0706245
23
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine 1993;329:977–86. doi:10.1056/NEJM199309303291401
24
Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. New England Journal of Medicine 2005;353:2643–53. doi:10.1056/NEJMoa052187
25
Orchard TJ, Nathan DM, Zinman B, et al. Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. JAMA 2015;313. doi:10.1001/jama.2014.16107
26
Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016;59:2298–307. doi:10.1007/s00125-016-4065-6
27
Bianchi C, Miccoli R, Del Prato S. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? Current Diabetes Reports 2013;13:403–10. doi:10.1007/s11892-013-0371-2
28
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine 2015;373:2117–28. doi:10.1056/NEJMoa1504720
29
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 2016;375:311–22. doi:10.1056/NEJMoa1603827
30
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343:d4169–d4169. doi:10.1136/bmj.d4169
31
Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. The Lancet 2009;373:1765–72. doi:10.1016/S0140-6736(09)60697-8
32
Sultan A, Perriard F, Macioce V, et al. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. Diabetic Medicine Published Online First: 18 April 2017. doi:10.1111/dme.13364
33
Rawshani A, Rawshani A, Franzén S, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine 2017;376:1407–18. doi:10.1056/NEJMoa1608664
34
Sultan A, Perriard F, Macioce V, et al. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. Diabetic Medicine Published Online First: 18 April 2017. doi:10.1111/dme.13364
35
Soliman EZ, Backlund J-YC, Bebu I, et al. Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2017;40:793–9. doi:10.2337/dc16-2050
36
Solomon SD, Chew E, Duh EJ, et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418. Diabetes Care 2017;40:809.3-809. doi:10.2337/dc17-er06e
37
Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012. New England Journal of Medicine 2017;376:1419–29. doi:10.1056/NEJMoa1610187
38
Rawshani A, Rawshani A, Franzén S, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine 2017;376:1407–18. doi:10.1056/NEJMoa1608664
39
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine 2017;377:300–1. doi:10.1056/NEJMc1706292
40
Older antidiabetic drugs | The British Journal of Cardiology. https://bjcardio.co.uk/2018/03/older-antidiabetic-drugs/
41
Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354
42
Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 2017;377:1228–39. doi:10.1056/NEJMoa1612917
43
Pickering RJ, Rosado CJ, Sharma A, et al. Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. Clinical & Translational Immunology 2018;7. doi:10.1002/cti2.1016
44
Microvascular Complications and Foot Care. Diabetes Care 2017;40:S88–98. doi:10.2337/dc17-S013
45
Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ Published Online First: 17 January 2017. doi:10.1136/bmj.i6505
46
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. The Lancet 2010;375:2215–22. doi:10.1016/S0140-6736(10)60484-9
47
The changing face of diabetes complications - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716300109
48
Wong MG, Perkovic V, Chalmers J, et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care 2016;39:694–700. doi:10.2337/dc15-2322
49
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. New England Journal of Medicine 2011;364:829–41. doi:10.1056/NEJMoa1008862
50
Wannamethee SG, Shaper AG, Whincup PH, et al. Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men: influence of age at onset, diabetes duration and established and novel rosk factors. Archives of Internal Medicine 2011;171. doi:10.1001/archinternmed.2011.2
51
Yudkin JS, Richter B, Gale EA. Intensified glucose control in type 2 diabetes—whose agenda? The Lancet 2011;377:1220–2. doi:10.1016/S0140-6736(10)61112-9
52
Zhang C-Y, Sun A-J, Zhang S-N, et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis. Annals of Medicine 2010;42:305–15. doi:10.3109/07853891003796752
53
Ele Ferrannini. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. European Heart Journal 2015;36:2288–96.http://eurheartj.oxfordjournals.org/content/36/34/2288
54
Fox CS, Golden SH, Anderson C, et al. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care 2015;38:1777–803. doi:10.2337/dci15-0012
55
Bianchi C, Miccoli R, Del Prato S. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? Current Diabetes Reports 2013;13:403–10. doi:10.1007/s11892-013-0371-2
56
Khunti K, Davies M, Majeed A, et al. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care 2015;38:316–22. doi:10.2337/dc14-0920
57
Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 2015;372:2197–206. doi:10.1056/NEJMoa1414266
58
Cefalu WT, Rosenstock J, LeRoith D, et al. Getting to the "Heart” of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory”. Diabetes Care 2016;39:664–7. doi:10.2337/dc16-0405
59
Black JA, Sharp SJ, Wareham NJ, et al. Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. British Journal of General Practice 2014;64:e208–16. doi:10.3399/bjgp14X677833
60
Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288–98. doi:10.1007/s00125-009-1470-0
61
Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. The Lancet Diabetes & Endocrinology 2017;5:431–7. doi:10.1016/S2213-8587(17)30104-3
62
Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354
63
Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials. International Journal of Cardiology 2010;141:157–66. doi:10.1016/j.ijcard.2008.11.211
64
Richard W. Nesto. LDL cholesterol lowering in type 2 diabetes: what is the optimum approach? Clinical Diabetes 2008;26.http://go.galegroup.com/ps/i.do?id=GALE|A174972167&v=2.1&u=leicester&it=r&p=EAIM&sw=w&asid=07d8e79bb8f42665bb52cc5732948c88
65
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine 2010;362:1563–74. doi:10.1056/NEJMoa1001282
66
Filippatos T, Tsimihodimos V, Pappa E, et al. Pathophysiology of diabetic dyslipidaemia. Current Vascular Pharmacology 2017;15:1–1.
67
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis 2016;252:207–74. doi:10.1016/j.atherosclerosis.2016.05.037
68
White J, Swerdlow DI, Preiss D, et al. Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. JAMA Cardiology 2016;1. doi:10.1001/jamacardio.2016.1884
69
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data - ClinicalKey. https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716000036
70
Hypertension: Clinical Management of Primary Hypertension in Adults | NICE guideline 127. August 2011. http://www.nice.org.uk/guidance/cg127
71
Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine 2010;362:1575–85. doi:10.1056/NEJMoa1001286
72
Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. The Lancet 2012;380:601–10. doi:10.1016/S0140-6736(12)60987-8
73
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ : British Medical Journal 1998;317.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC28659/
74
Whelton PK. Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia. Archives of Internal Medicine 2005;165. doi:10.1001/archinte.165.12.1401
75
Barzilay JI, Davis BR, Pressel SL, et al. Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study. Circulation: Cardiovascular Quality and Outcomes 2012;5:153–62. doi:10.1161/CIRCOUTCOMES.111.962522
76
Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet 2002;359:1004–10. doi:10.1016/S0140-6736(02)08090-X
77
Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet 2005;366:895–906. doi:10.1016/S0140-6736(05)67185-1
78
Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. Journal of the American College of Cardiology 2010;56:77–85. doi:10.1016/j.jacc.2010.02.046
79
Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. The Lancet 2007;369:201–7. doi:10.1016/S0140-6736(07)60108-1
80
Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine 2010;362:1575–85. doi:10.1056/NEJMoa1001286
81
Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. Diabetologia 1996;39:1646–54. doi:10.1007/s001250050629
82
Bangalore S, Kumar S, Lobach I, et al. Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials. Circulation 2011;123:2799–810. doi:10.1161/CIRCULATIONAHA.110.016337
83
Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus. Archives of Internal Medicine 2005;165. doi:10.1001/archinte.165.12.1410
84
Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey. https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2213858718300020
85
Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300998
86
Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300020
87
Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–8. doi:10.2337/dc16-2641
88
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. The Lancet 2010;376:124–36. doi:10.1016/S0140-6736(09)62124-3
89
Adamsson Eryd S, Svensson A-M, Franzén S, et al. Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up. Diabetic Medicine 2017;34:411–8. doi:10.1111/dme.13266
90
Liew G, Mitchell P, Wong TY. Systemic management of diabetic retinopathy. BMJ 2009;338:b441–b441. doi:10.1136/bmj.b441
91
Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, et al. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. British Journal of Ophthalmology Published Online First: 7 March 2017. doi:10.1136/bjophthalmol-2016-310063
92
Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, et al. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. British Journal of Ophthalmology Published Online First: 7 March 2017. doi:10.1136/bjophthalmol-2016-310063
93
Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, et al. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. British Journal of Ophthalmology Published Online First: 7 March 2017. doi:10.1136/bjophthalmol-2016-310063
94
Solomon SD, Chew E, Duh EJ, et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418. Diabetes Care Published Online First: 21 April 2017. doi:10.2337/dc17-er06e
95
Solomon SD, Chew E, Duh EJ, et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418. Diabetes Care Published Online First: 21 April 2017. doi:10.2337/dc17-er06e
96
Rosenberg JB, Tsui I. Screening for Diabetic Retinopathy. New England Journal of Medicine 2017;376:1587–8. doi:10.1056/NEJMe1701820
97
Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. New England Journal of Medicine 2017;376:1507–16. doi:10.1056/NEJMoa1612836
98
Moreton RBR, Stratton IM, Chave SJ, et al. Factors determining uptake of diabetic retinopathy screening in Oxfordshire. Diabetic Medicine 2017;34:993–9. doi:10.1111/dme.13350
99
Melanie Davies. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clinical Pharmacology : Advances and Applications 2016;8. doi:doi: 10.2147/CPAA.S82008
100
Navaneethan SD, Schold JD, Jolly SE, et al. Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD. American Journal of Kidney Diseases Published Online First: February 2017. doi:10.1053/j.ajkd.2016.11.018
101
Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME - ClinicalKey. https://www.clinicalkey.com/#!/content/journal/1-s2.0-S1262363617300022
102
Webb DR, Zaccardi F, Davies MJ, et al. Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes. Diabetes/Metabolism Research and Reviews Published Online First: 2016. doi:10.1002/dmrr.2877
103
Çakici N, Fakkel TM, van Neck JW, et al. Systematic review of treatments for diabetic peripheral neuropathy. Diabetic Medicine 2016;33:1466–76. doi:10.1111/dme.13083
104
Koye DN, Shaw JE, Reid CM, et al. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. Diabetic Medicine Published Online First: February 2017. doi:10.1111/dme.13324
105
Johal S, Jackson-Spence F, Gillott H, et al. Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study. Diabetic Medicine Published Online First: 5 June 2017. doi:10.1111/dme.13383
106
Clokie M, Greenway AL, Harding K, et al. New horizons in the understanding of the causes and management of diabetic foot disease: report from the 2017 Diabetes UK Annual Professional Conference Symposium. Diabetic Medicine 2017;34:305–15. doi:10.1111/dme.13313
107
Game F. Classification of diabetic foot ulcers. Diabetes/Metabolism Research and Reviews 2016;32:186–94. doi:10.1002/dmrr.2746
108
Jhamb S, Vangaveti VN, Malabu UH. Genetic and molecular basis of diabetic foot ulcers: Clinical review. Journal of Tissue Viability 2016;25:229–36. doi:10.1016/j.jtv.2016.06.005
109
Boulton AJ, Jeffcoate WJ, Jones TL, et al. International collaborative research on Charcot’s disease - 2009. The Lancet 2009;373:105–6. doi:10.1016/S0140-6736(09)60019-2
110
Yavuz M, Ersen A, Hartos J, et al. Plantar Shear Stress in Individuals With a History of Diabetic Foot Ulcer: An Emerging Predictive Marker for Foot Ulceration. Diabetes Care 2017;40:e14–5. doi:10.2337/dc16-2204
111
P Naidoo. Lower limb complications of diabetes mellitus: a comprehensive review with clinicopathological insights from a dedicated high-risk diabetic foot multidisciplinary team. The British Journal of Radiology 2015;88. doi:doi: 10.1259/bjr.20150135
112
Diabetic foot problems: prevention and management | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/ng19
113
Holt RIG. Understanding of the causes and management of diabetic foot disease. Diabetic Medicine 2017;34:303–4. doi:10.1111/dme.13319
114
Jin D, Xu Y, Geng D, et al. Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice 2010;89:10–5. doi:10.1016/j.diabres.2010.03.021
115
Çakici N, Fakkel TM, van Neck JW, et al. Systematic review of treatments for diabetic peripheral neuropathy. Diabetic Medicine 2016;33:1466–76. doi:10.1111/dme.13083
116
Foresta C, Ferlin A, Lenzi A, et al. The great opportunity of the andrological patient: cardiovascular and metabolic risk assessment and prevention. Andrology Published Online First: March 2017. doi:10.1111/andr.12342
117
Azmi S, Ferdousi M, Alam U, et al. Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study. Diabetologia Published Online First: 29 March 2017. doi:10.1007/s00125-017-4245-z
118
Andersson DP, Trolle Lagerros Y, Grotta A, et al. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart Published Online First: 9 March 2017. doi:10.1136/heartjnl-2016-310746
119
Omland T, Randby A, Hrubos-Strøm H, et al. Relation of Erectile Dysfunction to Subclinical Myocardial Injury. The American Journal of Cardiology 2016;118:1821–5. doi:10.1016/j.amjcard.2016.08.070
120
Braffett BH, Wessells H, Sarma AV. Urogenital Autonomic Dysfunction in Diabetes. Current Diabetes Reports 2016;16. doi:10.1007/s11892-016-0824-5
121
Hotaling JM, Sarma AV, Patel DP, et al. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. Diabetes Care 2016;39:1587–93. doi:10.2337/dc16-0059
122
Giovanni Corona. Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors. PLoS ONE 2016;11. doi:doi: 10.1371/journal.pone.0157915
123
Santi D, Granata ARM, Guidi A, et al. Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. European Journal of Endocrinology 2016;174:513–22. doi:10.1530/EJE-15-1100
124
Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321
125
Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321
126
Malavige LS, Wijesekara P, Ranasinghe P, et al. The association between physical activity and sexual dysfunction in patients with diabetes mellitus of European and South Asian origin: The Oxford Sexual Dysfunction Study. European Journal of Medical Research 2015;20. doi:10.1186/s40001-015-0186-5
127
Hotaling JM, Sarma AV, Patel DP, et al. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. Diabetes Care 2016;39:1587–93. doi:10.2337/dc16-0059
128
Dhatariya KK, Vellanki P. Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA). Current Diabetes Reports 2017;17. doi:10.1007/s11892-017-0857-4
129
Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality. Primehttps://wwww.unboundmedicine.com/medline/citation/22586788/Assessing_the_relationship_between_admission_glucose_levels_subsequent_length_of_hospital_stay_readmission_and_mortality_
130
Dhatariya K, Levy N, Kilvert A, et al. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. Diabetic Medicine 2012;29:420–33. doi:10.1111/j.1464-5491.2012.03582.x
131
The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management - ClinicalKey. https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0026049515003728
132
Scott AR. Management of hyperosmolar hyperglycaemic state in adults with diabetes. Diabetic Medicine 2015;32:714–24. doi:10.1111/dme.12757
133
Ian Blumer, MD, FRCPC1, 2, Maureen Clement, MD, CCFP3, ,. Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges. Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challengeshttp://www.sciencedirect.com.ezproxy4.lib.le.ac.uk/science/article/pii/S0149291816307792
134
Chloe L. Edridge. Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. PLoS ONE 2015;10. doi:doi: 10.1371/journal.pone.0126427
135
Khunti K, Davies M, Majeed A, et al. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care 2015;38:316–22. doi:10.2337/dc14-0920
136
Minimizing Hypoglycemia in Diabetes: Table 1. Diabetes Care 2015;38:1583–91. doi:10.2337/dc15-0279
137
Zaccardi F, Webb DR, Davies MJ, et al. Predicting hospital stay, mortality and readmission in people admitted for hypoglycaemia: prognostic models derivation and validation. Diabetologia Published Online First: 17 March 2017. doi:10.1007/s00125-017-4235-1
138
Zaccardi F, Webb DR, Davies MJ, et al. Risk factors and outcome differences in hypoglycaemia-related hospital admissions: A case-control study in England. Diabetes, Obesity and Metabolism Published Online First: April 2017. doi:10.1111/dom.12941
139
Umpierrez G, Korytkowski M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nature Reviews Endocrinology 2016;12:222–32. doi:10.1038/nrendo.2016.15
140
Umpierrez G, Korytkowski M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nature Reviews Endocrinology 2016;12:222–32. doi:10.1038/nrendo.2016.15
141
Micha R, Peñalvo JL, Cudhea F, et al. Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States. JAMA 2017;317. doi:10.1001/jama.2017.0947
142
Khunti K, Wolden ML, Thorsted BL, et al. Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people. Diabetes Care 2013;36:3411–7. doi:10.2337/dc13-0331
143
Paul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology 2015;14. doi:10.1186/s12933-015-0260-x
144
Nicolucci A, Standl E. Antiplatelet Therapy for Every Diabetic Person? Diabetes Care 2011;34:S150–4. doi:10.2337/dc11-s210
145
Seidu S, Achana FA, Gray LJ, et al. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. Diabetic Medicine 2016;33:280–9. doi:10.1111/dme.12885
146
The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management - NHS Health Check. http://www.healthcheck.nhs.uk/news/the_handbook_for_vascular_risk_assessment_risk_reduction_and_risk_management/
147
Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabetic Medicine 2017;34:316–27. doi:10.1111/dme.13133
148
Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. Diabetic Medicine 2014;31:764–72. doi:10.1111/dme.12428
149
Dana Dabelea. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. JAMA;317:825–35. doi:10.1001/jama.2017.0686
150
Personalised treatment targets in type 2 diabetes patients: The Dutch approach - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1751991816300626
151
Dwamena F, Holmes-Rovner M, Gaulden CM, et al. Interventions for providers to promote a patient-centred approach in clinical consultations. In: Cochrane Database of Systematic Reviews. Chichester, UK: : John Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD003267.pub2
152
Proceedings of the 5th International DAWN Summit 2014: Acting together to make person-centred diabetes care a reality - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822715001862
153
Denig P, Schuling J, Haaijer-Ruskamp F, et al. Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial. BMJ 2014;349:g5651–g5651. doi:10.1136/bmj.g5651
154
Abdul-Ghani M, DeFronzo RA, Del Prato S, et al. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017;40:813–20. doi:10.2337/dc16-2736
155
Kaul S. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–31. doi:10.2337/dc17-0291
156
Ritholz MD, MacNeil T, Weinger K. Difficult conversations: adults with diabetes and the discussion of microvascular complications. Diabetic Medicine Published Online First: 13 July 2017. doi:10.1111/dme.13419
157
Ritholz MD, MacNeil T, Weinger K. Difficult conversations: adults with diabetes and the discussion of microvascular complications. Diabetic Medicine 2017;34:1447–55. doi:10.1111/dme.13419
158
Holt RIG, Cockram CS, Flyvbjerg A, et al., editors. Textbook of diabetes. Fifth edition. Chichester, West Sussex, UK: : Wiley Blackwell 2017. http://ezproxy.lib.le.ac.uk/login?url=http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=4769056
159
Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354
